Herbal hepatotoxicity: A hidden epidemic

Internal and Emergency Medicine

Volumn 8, Issue 1, 2013, Pages 13-22

  Licata, Anna ^a   Macaluso, Fabio Salvatore ^a   Craxì, Antonio ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Dietary supplement (DS); Hepatotoxicity; Herbal remedies (HRs); Prevention; Slimming aids

Indexed keywords

EID: 84873154377     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-012-0777-x     Document Type: Review

References (80)

1. Tyler VE, Foster S (1999) Tyler's Honest Herbal; The Physicians' Desk Reference for Herbal Medicines (annual).
2. Goldman P (2001) Herbal medicine today and the roots of modern pathology. Ann Intern Med 135: 594-600.
3. Stickel F, Schuppan D (2007) Herbal medicine in the treatment of liver diseases. Dig Liver Dis 39: 293-304.
4. Calapai G (2008) European legislation on herbal medicines: a look into the future. Drug Saf 31: 428-431.
5. Menniti-Ippolito F, Mazzanti G, Santuccio C, Moro P, Calapai G, Firenzuoli F et al (2008) Surveillance of suspected adverse reactions to natural health products in Italy. Pharmacoepidemiol Drug Saf 17: 626-635.
6. Kessler RC, Davis RB, Foster DF, van Rompay MI, Walters EE, Wilkey SA et al (2001) Long-term trends in the use of complementary and alternative medical therapies in the United States. Ann Intern Med 135: 262-268.
7. Navarro V (2009) Herbal and dietary supplement hepatotoxicity. Sem Liv Dis 29: 3733-3782.
8. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA et al (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30: 239-245.
9. Danan G, Benichou C (1993) Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 46: 1323-1330.
10. Maria VA, Victorino RM (1997) Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 26: 664-669.
11. Watanabe M, Shibuya A (2004) Validity study of a new diagnostic scale for drug-induced liver injury in Japan-comparison with two previous scales. Hepatol Res 30: 148-154.
12. Strader DB, Bacon BR, Lindsay KL, La Breque DR, Morgan T, Wright EC et al (2002) Use of complementary and alternative medicine in patients with liver disease. Am J Gastroenterol 97: 2391-2397.
13. Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, van Rompay M et al (1998) Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 280: 1569-1575.
14. Stickel F, Patsenker E, Schuppan D (2005) Herbal hepatotoxicity. J Hepatol 43: 901-910.
15. National Institute of Statistic (2007) Le terapie non convenzionali in Italia. ISTAT, Rome.
16. Vitalone A, Menniti-Ippolito F, Moro PA, Firenzuoli F, Raschetti R et al (2011) Suspected adverse reactions associated with herbal products used for weight loss: a case series reported to the Italian National Institute of Health. Eur J Clin Pharmacol 67: 215-224.
17. Menniti-Ippolito F, Forcella E, Bologna E, Gargiulo L, Traversa G, Raschetti R (2002) Use of unconventional medicine in children in Italy. Eur J Pediatr 161: 690.
18. Zaffani S, Cuzzolin L, Benoni G (2006) Herbal products: behaviours and beliefs among Italian women. Pharmacoepidemiol Drug Saf 15: 354-359.
19. Gardner DR, Panter KE, James LF, Stegelmeier BL (1998) Abortifacient effects of lodgepole pine (Pinus contorta) and common juniper (Juniperus communis) on cattle. Vet Hum Toxicol 40: 260-263.
20. Bilgi N, Bell K, Ananthakrishnan AN, Atallah E (2010) Imatinib and Panax ginseng: a potential interaction resulting in liver toxicity. Ann Pharmacother 44: 926-928.
21. Kocaman O, Hulagu S, Senturk O (2008) Echinacea-induced severe acute hepatitis with features of cholestatic autoimmune hepatitis. Eur J Intern Med 19: 148.
22. Lucenteforte E, Gallo E, Pugi A, Giommoni F, Paoletti A, Vietri M et al. (2011) Complementary and alternative drugs use among preoperative patients: a cross-sectional study in Italy. Evid Based Complement Alternat Med. doi: 10. 1155/2012/527238.
23. Sarma DN, Barrett ML, Chavez ML, Gardiner P, Ko R, Mahady GB et al (2008) Safety of green tea extracts. A systematic review by the US pharmacopeia. Drug Saf 31: 469-484.
24. Mazzanti G, Menniti-Ippolito F, Moro PA, Cassetti F, Raschetti R, Santuccio C et al (2009) Hepatotoxicity from green tea: a review of the literature and two unpublished cases. Eur J Clin Pharmacol 65: 331-341.
25. Stickel F, Kessebohm K, Weimann R, Seitz HK (2011) Review of liver injury associated with dietary supplements. Liver Int 31: 595-605.
26. Galati G, Lin A, Sultan AM, O'Brien PJ (2006) Cellular and in vivo hepatotoxicity caused by green tea phenolic acids and catechins. Free Radic Biol Med 40: 570-580.
27. Jin X, Zheng RH, Li YM (2008) Green tea consumption and liver disease: a systematic review. Liver Int 28: 990-996.
28. Yang CS, Lambert JD, Ju J, Lu G, Sang S (2007) Tea and cancer prevention: molecular mechanisms and human relevance. Toxicol Appl Pharmacol 224: 265-273.
29. Weston CFM, Cooper BT, Davies JD, Levine DF (1987) Veno-occlusive disease of the liver secondary to ingestion of comfrey. BMJ 295: 183.
30. Stickel F, Seitz HK (2000) The efficacy and safety of comfrey. Pub Health Nutr 3: 501-508.
31. Kassler WJ, Blanc P, Greenblatt R (1991) The use of medicinal herbs by human immunodeficiency virus-infected patients. Arch Intern Med 151: 2281-2288.
32. Sheikh NM, Philen RM, Love LA (1997) Chaparral-associated hepatotoxicity. Arch Intern Med 157: 913-919.
33. Agarwal R, Wang ZY, Bik DP, Mukhtar H (1991) Nordihydroguaiaretic acid, an inhibitor of lipoxygenase, also inhibits cytochrome P-450-mediated monooxygenase activity in rat epidermal and hepatic microsomes. Drug Metab Dispos 19: 620-624.
34. Stevinson C, Ernst E (2000) Valerian for insomnia: a systematic review of randomized clinical trials. Sleep Med 1: 91-99.
35. Lefebvre T, Foster BC, Drouin CE, Krantis A, Livesey JF, Jordan SA (2004) In vitro activity of commercial valerian root extracts against human cytochrome P450 3A4. J Pharm Pharm Sci 7: 265-273.
36. Cohen DL, Del Toro Y (2008) A case of valerian-associated hepatotoxicity. J Clin Gastroenterol 42: 961-962.
37. Vassiliadis T, Anagnostis P, Patsiaoura K, Giouleme O, Katsinelos P, Mpoumponaris A et al (2009) Valeriana hepatotoxicity. Sleep Med 10: 935.
38. Piccolo P, Gentile S, Alegiani F, Angelico M (2009) Severe drug induced acute hepatitis associated with use of St John's wort (Hypericum perforatum) during treatment with pegylated interferon α. BMJ Case Rep. doi: 10. 1136/bcr. 08. 2008. 0761.
39. Etogo-Asse F, Boemer F, Sempoux C, Geubel A (2008) Acute hepatitis with prolonged cholestasis and disappearance of interlobular bile ducts following tibolone and Hypericum perforatum (St. John's wort). Case of drug interaction? Acta Gastroenterol Belg 71: 36-38.
40. Stedman C (2002) Herbal hepatotoxicity. Semin Liver Dis 22: 195-206.
41. Woolf GM, Petrovic LM, Roiter SE, Wainwright S, Villamil FG, Katkov WN et al (1994) Acute hepatitis associated with the Chinese herbal product Jin Bu Huan. Ann Intern Med 121: 729-735.
42. Picciotto A, Campo N, Brizzolara R, Giusto R, Guido G, Sinelli N et al (1998) Chronic hepatitis induced by Jin Bu Huan. J Hepatol 28: 165-167.
43. World Health Organization (2007) Assessments of the risk of hepatotoxicity with kava products. WHO Document Production Services, Geneva.
44. Teschke R, Schwarzenboeck A, Hennermann KH (2008) Kava hepatotoxicity: a clinical survey and critical analysis of 26 suspected cases. Eur J Gastroenterol Hepatol 20: 1182-1193.
45. Teschke R, Schwarzenboeck A, Akinci A (2008) Kava hepatotoxicity: a European view. N Z Med J 121: 90-98.
46. Teschke R (2010) Kava hepatotoxicity-a clinical review. Ann Hepatol 9: 251-265.
47. Teschke R (2010) Kava hepatotoxicity: pathogenetic aspects and prospective considerations. Liver Int 30: 1270-1279.
48. Colombo ML, Bosisio E (1996) Pharmacological activities of Chelidonium majus L. (Papaveraceae). Pharmacol Res 33: 127-134.
49. Moro PA, Cassetti F, Giugliano G, Falce MT, Mozzanti G, Menniti-Ippolito F et al (2009) Hepatitis from Greater celandine (Chelidonium majus L.): review of literature and report of a new case. J Ethnopharmacol 124: 328-332.
50. Greving I, Meister V, Monnerjahn C, Muller KM, May B (1998) Chelidonium majus: a rare reason for severe hepatotoxic reaction. Pharmacoepidemiol Drug Safety 7: S66-S69.
51. Larrey D (1997) Hepatotoxicity of herbal remedies. J Hepatol 26: 47-51.
52. Obatomi DK, Brant S, Anthony-Pillai V, Bach PH (1998) Toxicity of atractylosides in precicion-cut rat and porcine renal and hepatic tissue slices. Toxicol Appl Pharmacol 148: 35-45.
53. Dunbar K, Solga SF (2007) Black cohosh, safety, and public awareness. Liver Int 27: 1017-1018.
54. Mahady GB, Low Dog T, Barrett ML, Chavez ML, Gardiner P, Ko R et al (2008) United States Pharmacopeia review of the black cohosh case reports of hepatotoxicity. Menopause 15: 628-638.
55. EMEA. Assessment of case reports connected to herbal medicinal products containing Cimicifugae racemosae rhizoma (black cohosh, root). Available at: http://www. emea. europa. eu/pdfs/human/hmpc/.
56. Teschke R (2010) Black cohosh and suspected hepatotoxicity: inconsistencies, confounding variables, and prospective use of a diagnostic causality algorithm. A critical review. Menopause 17: 426-440.
57. Firenzuoli F, Gori L, di Sarsina PR (2011) Black cohosh hepatic safety: follow-up of 107 patients consuming a special Cimicifuga racemosa rhizome herbal extract and review of literature. Evid Based Complement Alternat Med. doi: 10. 1093/ecam/nen009.
58. US Food and Drug Administration. Warning on Hydroxycut products. Available at http://www. fda. gov.
59. Dara L, Hewett J, Lim JK (2008) Hydroxycut hepatotoxicity: a case series and review of liver toxicity from herbal weight loss supplements. World J Gastroenterol 14: 6999-7004.
60. Fong TL, Klontz KC, Canas-Coto A, Casper SJ, Durazo FA et al (2010) Hepatotoxicity due to Hydroxycut: a case series. Am J Gastroenterol 105: 1561-1566.
61. Lobb A (2009) Hepatoxicity associated with weight-loss supplements: a case for better post-marketing surveillance. World J Gastroenterol 15: 1786-1787.
62. Nadir A, Agrawal S, King P, King PD, Marshall JB (1996) Acute hepatitis associated with the use of a chinese herbal product, Ma huang. Am J Gastoenterol 91: 1436-1438.
63. Borum ML (2001) Fulminant exacerbation of autoimmune hepatitis after the use of Ma huang. Am J Gastroenterol 96: 1654-1655.
64. Skoulidis F, Alexander GJ, Davies SE (2005) Ma huang associated acute liver failure requiring liver transplantation. Eur J Gastroenterol Hepatol 17: 581-584.
65. Bajaj J, Knox JF, Komorowski R, Saeian K (2003) The irony of herbal hepatitis. Ma-huang induced hepatotoxicity associated with compound heterozygosity for hereditary hemochromatosis. Dig Dis Sci 48: 1925-1928.
66. Favreau JT, Ryu ML, Braunstein G, Orshansky G, Park SS, Coody GL et al (2002) Severe hepatotoxicity associated with the dietary supplement LipoKinetix. Ann Intern Med 136: 590-595.
67. Durazo FA, Lassman C, Han SH, Saab S, Lee NP, Kawano M et al (2004) Fulminant liver failure due to usnic acid for weight loss. Am J Gastroenterol 99: 950-952.
68. Sanchez W, Maple JT, Burgart LJ, Kamath PS (2006) Severe hepatotoxicity associated with use of a dietary supplement containing usnic acid. Mayo Clin Proc 81: 541-544.
69. Han D, Matsumaru K, Rettori D, Kaplowitz N (2004) Usnic acid-induced necrosis of cultured mouse hepatocytes: inhibition of mitochondrial function and oxidative stress. Biochem Pharmacol 67: 439-451.
70. Gori L, Galluzzi P, Mascherini V, Gallo E, Lapi F et al (2011) Two contemporary cases of hepatitis associated with Teucrium chamaedrys L. Decoction use. Case reports and review of literature. Basic Clin Pharmacol Toxicol 109: 521-526.
71. Mazokopakis E, Lazaridou S, Tzardi M, Mixaki J, Diamantis I et al (2004) Acute cholestatic hepatitis caused by Teucrium polium L. Phytomedicine 11: 83-84.
72. Lekehal M, Pessayre D, Lereau JM, Moulis C, Fouraste I, Fau D (1996) Hepatotoxicity of the herbal medicine, germander, metabolic activation of its furano diterpenoids by cytochrome P450 3A depletes cytoskeleton-associated protein thiols and forms plasma membrane blebs in rat hepatocytes. Hepatology 24: 212-218.
73. Elinav E, Pinsker G, Safadi R, Pappo O, Bromberg M, Anis E et al (2007) Association between consumption of Herbalifes nutritional supplements and acute hepatotoxicity. J Hepatol 47: 514-520.
74. Schoepfer AM, Engel A, Fattinger K, Marbet UA, Criblez D, Reichen J et al (2007) Herbal does not mean innocuous: 10 cases of severe hepatotoxicity associated with dietary supplements from Herbalifes products. J Hepatol 47: 521-526.
75. Duque JM, Ferreiro J, Salgueiro E, Manso G (2007) Hepatotoxicity associated with the consumption of herbal slimming products. Med Clin (Barc) 128: 238-239.
76. Chao S, Anders M, Turbay M, Olaiz E, Mc Cormack L, Mastai R (2008) Toxic hepatitis by consumption Herbalife products a case report. Acta Gastroenterol Latinoam 38: 274-277.
77. Stickel F, Droz S, Patsenker E, Bögli-Stuber K, Aebi B, Leib SL (2009) Severe hepatotoxicity following ingestion of Herbalifes nutritional supplements contaminated with Bacillus subtilis. J Hepatol 50: 111-117.
78. Johannsson M, Ormarsdottir S, Olafsson S (2010) Hepatotoxicity associated with the use of Herbalife. Laeknabladid 96: 167-172.
79. Lin G, Wang JY, Li N, Gao H, Ji Y, Zhang F et al (2010) Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum. J Hepatol 54: 666-673.
80. Larrey D, Faure S (2011) Herbal medicine hepatotoxicity: a new step with development of specific biomarkers. J Hepatol 54: 599-601.